Based on these results, avelumab 1L maintenance was approved for patients with la/mUC that had not progressed with 1L platinum-based chemotherapy [2], regardless of tumor PD-L1 expression; it is now recommended as the standard of care in international treatment guidelines [3, 4]. This evidence concerns the gene CD274 and neoplasm.